Treatment of acute hepatitis C in breast cancer patient: a case report

References

• Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.
   PubMed Web of Science ®Google Scholar
• Koike K. Antiviral treatment of hepatitis C: present status and future prospects. J Infect Chemother. 2006;12:227–32.
   PubMedGoogle Scholar
• Roferon-A [package insert] by Hoffmann-La Roche Inc.; 2008. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid = 4c918b02-f158-4f7c-8ecc-fd49574ec228. (accessed on 2013 March 4).
   Google Scholar
• Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening inpatients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010;28:3199–202.
   PubMed Web of Science ®Google Scholar
• Macedo de Oliveira A, White KL, Leschinsky DP, Beecham BD, Vogt TM, Moolenaar RL, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005;142(11):898–902.
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008;372:321–32.
   PubMed Web of Science ®Google Scholar
• Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther. 2006;23:1153–9.
   PubMed Web of Science ®Google Scholar
• Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, de Lucas S, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189:7–14.
   PubMed Web of Science ®Google Scholar
• Semmo N, Barnes E, Taylor C, Kurtz J, Harcourt G, Smith N, et al. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet. 2005;365:327–9.
   PubMed Web of Science ®Google Scholar
• Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004;189:1846–55.
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 2002;3:333–40.
   PubMed Web of Science ®Google Scholar
• Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol). 2004;16:204–5.
   PubMed Web of Science ®Google Scholar
• Thiel J, Peters T, Mas Marques A, Rösler B, Peter HH, Weiner SM. Kinetics of hepatitis C (HCV) viraemia and quasispecies during treatment of HCV associated cryoglobulinaemia with pulse cyclophosphamide. Ann Rheum Dis. 2002;61:838–41.
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterol. 2003;125:80–8.
   PubMed Web of Science ®Google Scholar
• Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. The flying publisher short guide to hepatitis C 2013. The Flying Publisher & Kamps; 2013, p. 66–68. Available from http://www.flyingpublisher.com/0013.php (accessed 13 June 2013).
   Google Scholar
• Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8:265–74.
   PubMed Web of Science ®Google Scholar
• Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res. 2011;31:545–52.
   PubMed Web of Science ®Google Scholar
• Santhanam S, Decatris M, O'Byrne K. Potential of interferon-alpha in solid tumours: part 2. BioDrugs. 2002;16:349–72.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer. 1993;68:352–6.
   PubMed Web of Science ®Google Scholar
• Papaevangelou V, Varsami M, Papadakis V, Zellos A, Parcharidou A, Papargyri S, et al. Hepatitis C treatment concomitant to chemotherapy as “salvage” therapy in children with hematologic malignancies. Pediatr Infect Dis J. 2010;29:277–80.
   PubMed Web of Science ®Google Scholar
• Dufour JF, Pradat P, Ruivard M, Hot A, Dumontet C, Broussolle C, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol. 2009;21:245–53.
   PubMed Web of Science ®Google Scholar
• Taxotere official Food and Drug Administration (FDA) information, side effects and uses. Available from URL: http://www.drugs.com/pro/taxotere.html#S14 (accessed on 2013 February 11).
   Google Scholar
• Morrow PK, Tarrand JJ, Taylor SH, Kau SW, Theriault RL, Hortobagyi GN, et al. Effects of chronic hepatitis C infection on the treatment of breast cancer patients. Ann Oncol. 2010;21:1233–6.
   PubMed Web of Science ®Google Scholar
• D'Angelo S, Deutscher M, Dickler M, Weinstock DM. Hepatitis C virus infection does not preclude standard breast cancer-directed therapy. Clin Breast Cancer. 2009;9:51–2.
   PubMed Web of Science ®Google Scholar
• Shoji H, Hashimoto K, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, et al. Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection. Oncology. 2012;82:228–33.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116:5119–25.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Parsa V, Liu CY, Fontana JA. Trastuzumab-induced hepatotoxicity. Ann Pharmacother. 2008;42:1497–501.
   PubMed Web of Science ®Google Scholar
• Tamori A, Kawajiri H, Takashima T, Motoyama H, Morikawa H, Enomoto M, et al. Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer? Am J Gastroenterol. 2011;106:1865–6.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Lévy V, Asselah T, Marcellin P, Scieux C, Adès L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–24.
   PubMed Web of Science ®Google Scholar